"
Team:Paris Bettencourt/Notebook/Template.html
From 2013.igem.org
(Difference between revisions)
| Line 21: | Line 21: | ||
pCOLADuet-1 (KanR) : <span style="color:red">CGTTTCCCGTTGAATATGGCTCAT</span><br /> | pCOLADuet-1 (KanR) : <span style="color:red">CGTTTCCCGTTGAATATGGCTCAT</span><br /> | ||
<br /> | <br /> | ||
| - | We decided that targeting only two different antibiotic resistance will be enough for a proof of concept. We give up AmpR because otherwise they might be experimental issues with AmpR that is also on phagemid litmus28i. | + | We decided that targeting only two different antibiotic resistance will be enough for a proof of concept. We give up AmpR because otherwise they might be experimental issues with AmpR that is also on phagemid <em>litmus28i</em>. |
</p> | </p> | ||
</div> | </div> | ||
</body> | </body> | ||
</html> | </html> | ||
Revision as of 23:59, 29 July 2013
Drug Screening
Day Number sup Month
sRNA design
Red sequences:
pACYCDuet-1 (CmR) : ATATCCAGTGATTTTTTTCTCCAT
pCOLADuet-1 (KanR) : CGTTTCCCGTTGAATATGGCTCAT
We decided that targeting only two different antibiotic resistance will be enough for a proof of concept. We give up AmpR because otherwise they might be experimental issues with AmpR that is also on phagemid litmus28i.
